University of Cambridge’s DIOS-CoVax2 COVID-19 candidate set for autumn human trials

On Wednesday, in a statement, the University of Cambridge said, it aims to start clinical trials of its COVID-19 candidate in autumn. The development comes in the wake following funding to the tune of 1.9 million pounds from the British government. The approach adopted by the scientists behind the vaccine uses genetic sequences of all…

COVID-19 patients respond positively to Gilead Sciences experimental drug

Shares of Gilead Sciences Inc’s shares jumped by 16% following news reports that its experimental drug remdesivir is proving to be effective in U.S. trials of patients who have been severely afflicted by the COVID-19 disease caused by the coronavirus. According to a report from medical news website STAT, a University of Chicago hospital participating…

Apple offers up to $1 million for remote access exploit for iPhones and cloud-based backups

Apple launched the challenge at the annual Black Hat security conference in Las Vegas. In order to remove exploitable vulnerabilities from its mobile operating system, Apple Inc has announced a bounty of up to $1 million to cyber security researchers who detect flaws in iPhones. This is the largest ever reward Apple has offered to…